The platform is being introduced to expand access to treatments for people living with chronic conditions
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The medicine was well tolerated, with no unexpected safety issue
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
EBITDA before special items decreases to €4.08 billion (7.4%)
Subscribe To Our Newsletter & Stay Updated